The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study
{{output}}
Background: Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (Ctrough), and similar t... ...
